Trial Profile
A Pilot, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Safety, Tolerability and Preliminary Efficacy Study of Two Dose Levels of IL-1 Trap Administered Subcutaneously in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Nov 2020
Price :
$35
*
At a glance
- Drugs Rilonacept (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 16 Nov 2020 Results (n=286) of meta-analysis of 5 studies assessing relative efficacy and safety of canakinumab, anakinra, tocilizumab, and rilonacept in patients with active sJIA, published in the International Journal of Clinical Pharmacology and Therapeutics.
- 27 Nov 2006 New trial record.